Video

Dr. Chi on the Utility of Liquid Biopsy in Prostate Cancer

Author(s):

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

Kim Chi, MD, senior research scientist, Vancouver Prostate Center, chief medical officer and vice president, BC Cancer, medical oncologist, BC Cancer, and professor, Department of Medicine, University of British Columbia, discusses the utility of liquid biopsy in prostate cancer.

In lung cancer, where liquid biopsy is more widely utilized, gene alterations can be detected with low levels of circulating tumor DNA (ctDNA), says Chi.

However, the same point mutations do not exist in prostate cancer, explained Chi. As such, a larger amount of ctDNA is required to appropriately identify an actionable mutation in these men.

Additionally, challenges regarding tissue testing in prostate cancer underscore the need for alternative testing modalities such as a liquid biopsy, says Chi.

Going forward, it is likely that blood-based testing will play a role in identifying men with DNA damage repair alterations, for example, to inform treatment decisions, concludes Chi.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity